Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: majormember who wrote (700)	4/17/1998 11:23:00 AM
From: EmuGreg	Read Replies (1) \| Respond to of 4140

A few other interesting observations from the article in this month's Review of Opthamology: 1) LTK was the only option for correcting hyperopia for which no disadvantages were discussed in the article. 2) Presbyopia is noted as a "far more difficult and universal refractive problem." And perhaps of greatest interest, the last sentence on the section regarding SNRS and LTK: "This procedure may win FDA approval as early as the end of this year." Shucks, I guess I'll have to rework all of my Present Value computations. Regards to all.